Prescription Digital Therapeutics for Attention Deficit Hyperactivity Disorder
Customize your policy alerts
Sign up for AmeriHealth Caritas Policy CCP.1470 alerts
Get alerted when Policy CCP.1470 changes without checking for updates manually.
Monitor payer policy activity
This policy governs coverage determinations for prescription digital therapeutics used to treat ADHD. EndeavorRx and Prismira, now marketed as LuminosityRx, are investigational and not medically necessary; medication and behavior management are alternative covered services.
Prismira, now marketed as LuminosityRx, was added as a prescription digital therapeutic considered investigational and not medically necessary.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.